These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34233956)

  • 1. What's yours is ours: waiving intellectual property protections for COVID-19 vaccines.
    Jecker NS; Atuire CA
    J Med Ethics; 2021 Sep; 47(9):595-598. PubMed ID: 34233956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness.
    Amin T; Kesselheim AS
    Inquiry; 2022; 59():469580221124821. PubMed ID: 36124939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Needle in a Haystack? Human Rights Framing at the World Trade Organization for Access to COVID-19 Vaccines.
    Perehudoff K; Qazilbash H; de Vries KF
    Health Hum Rights; 2022 Dec; 24(2):141-157. PubMed ID: 36579306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIPS waiver of COVID-19 vaccines: Impact on pharmaceutical industry and what it means to developing countries.
    Chaudhary T; Chaudhary A
    J World Intellect Prop; 2021 Nov; 24(5-6):447-454. PubMed ID: 34908905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.
    Chattu VK; Singh B; Kaur J; Jakovljevic M
    Biomed Res Int; 2021; 2021():6658070. PubMed ID: 34485525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intellectual Property and the Politics of Public Good during COVID-19: Framing Law, Institutions, and Ideas during TRIPS Waiver Negotiations at the WTO.
    Fischer SE; Vitale L; Agutu AL; Kavanagh MM
    J Health Polit Policy Law; 2024 Feb; 49(1):9-42. PubMed ID: 37522338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19.
    Kulkarni SM; Kaur V
    Pharm Pat Anal; 2022 Nov; 11(6):165-174. PubMed ID: 36314462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporary waiver of intellectual property on Covid-19 vaccines: toward the creation of a better, post-pandemic society.
    Del Castillo FA
    J Public Health (Oxf); 2021 Sep; 43(3):e559-e560. PubMed ID: 34056662
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 and Global Distributive Justice: 'Health Diplomacy' of India and South Africa for the TRIPS waiver.
    Singh B; Chattu VK; Kaur J; Mol R; Gauttam P; Singh B
    J Asian Afr Stud; 2023 Aug; 58(5):747-765. PubMed ID: 37461426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.
    Park SP; Lee HJ; Yu Y; Lee EYJ; Park YS
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 38035734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Waiving intellectual property rights: Boom or bust for medical innovation?
    Rake B
    Drug Discov Today; 2022 Feb; 27(2):384-389. PubMed ID: 34718204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing the Morality of Owning and Suspending Patent Rights for COVID-19 Vaccines in the Light of Catholic Social Teaching.
    Ballano VO
    Linacre Q; 2022 Feb; 89(1):47-63. PubMed ID: 35321490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders.
    Kohler J; Wong A; Tailor L
    Health Hum Rights; 2022 Dec; 24(2):159-175. PubMed ID: 36579316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicaments during a period of health emergency: Waiving patent protections or innovative public procurement? The example of advance purchase agreements (APA) for COVID-19 vaccines.
    Garrido Cuenca N
    Int J Risk Saf Med; 2022; 33(2):145-156. PubMed ID: 35213327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine passports and health disparities: a perilous journey.
    Jecker NS
    J Med Ethics; 2022 Dec; 48(12):957-960. PubMed ID: 34244344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem.
    Barnes-Weise J; Santos Rutschman A; Adler R
    J Epidemiol Community Health; 2022 Apr; 76(4):317-318. PubMed ID: 35140119
    [No Abstract]   [Full Text] [Related]  

  • 18. Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine.
    Sekalala S; Forman L; Hodgson T; Mulumba M; Namyalo-Ganafa H; Meier BM
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34253631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New WTO leader faces COVID-19 challenges.
    Zarocostas J
    Lancet; 2021 Feb; 397(10276):782. PubMed ID: 33640051
    [No Abstract]   [Full Text] [Related]  

  • 20. The COVID-19 vaccine patent: a right without rationale.
    Althabhawi NM; Kashef Al-Ghetaa AA
    Med Humanit; 2023 Mar; 49(1):128-133. PubMed ID: 35523578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.